Yellow Jersey Therapeutics Ag

This study tested a new drug called NM26-2198 for moderate-to-severe eczema (atopic dermatitis). It included healthy volunteers and patients, giving single or multiple doses to check safety and how the body processes the drug. The trial was terminated early, so results are limite…